GEN Exclusives

More »

GEN News Highlights

More »
Sep 25, 2008

bioMérieux Licenses ProteoSys’ Prostate Cancer Biomarker

  • bioMérieux and ProteoSys inked a deal for the use of the latter’s Annexin 3 biomarker in a urine-based, confirmatory diagnostic for prostate cancer. bioMérieux is also considering the use of Annexin prognostic applications.

    After a research phase, the test will be developed on the bioMérieux’ Vidas® platform. This Annexin 3-based diagnostic along with the standard screening methods could potentially reduce the number of biopsies conducted by up to 75%, according to bioMérieux.

    Studies have shown that quantification of Annexin 3, also known as ANXA 3, in urine has high specificity for prostate cancer, the companies report. Today, when the levels of PSA are in the uninformative grey zone, a biopsy is used to provide definitive diagnosis. The ANXA 3 test would be used to provide better identification of patients with a high probability of prostate cancer, thereby reducing the number of unnecessary biopsies.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?